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Abstract
Introduction: Treatment failure in acute myeloid leukemia is probably caused by the presence of leukemia initiating cells,
also referred to as leukemic stem cells, at diagnosis and their persistence after therapy. Specific identification of leukemia
stem cells and their discrimination from normal hematopoietic stem cells would greatly contribute to risk stratification and
could predict possible relapses.
Results: For identification of leukemic stem cells, we developed flow cytometric methods using leukemic stem cell
associated markers and newly-defined (light scatter) aberrancies. The nature of the putative leukemic stem cells and normal
hematopoietic stem cells, present in the same patient’s bone marrow, was demonstrated in eight patients by the presence
or absence of molecular aberrancies and/or leukemic engraftment in NOD-SCID IL-2Rc-/- mice. At diagnosis (n = 88), the
frequency of the thus defined neoplastic part of CD34+CD38- putative stem cell compartment had a strong prognostic
impact, while the neoplastic parts of the CD34+CD38+ and CD34- putative stem cell compartments had no prognostic
impact at all. After different courses of therapy, higher percentages of neoplastic CD34+CD38- cells in complete remission
strongly correlated with shorter patient survival (n = 91). Moreover, combining neoplastic CD34+CD38- frequencies with
frequencies of minimal residual disease cells (n = 91), which reflect the total neoplastic burden, revealed four patient groups
with different survival.
Conclusion and Perspective: Discrimination between putative leukemia stem cells and normal hematopoietic stem cells in
this large-scale study allowed to demonstrate the clinical importance of putative CD34+CD38- leukemia stem cells in AML.
Moreover, it offers new opportunities for the development of therapies directed against leukemia stem cells, that would
spare normal hematopoietic stem cells, and, moreover, enables in vivo and ex vivo screening for potential efficacy and
toxicity of new therapies.
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Introduction
There is increasing evidence that the development of solid and
hematological tumors depends on the presence of small popula-
tions of cells known as tumor-initiating cells or tumor stem cells
[1]. The first proof of the stem cell concept came from studies by
John Dick and colleagues in acute myeloid leukemia (AML) [2,3].
In AML, these cells are referred to as leukemia-initiating cells or
leukemic stem cells (LSCs) [4]. Since the first studies on LSCs, cell
compartments defined by immunophenotype (CD34/CD38
expression) and function (side population, SP, and aldehyde
dehydrogenase [ALDH] activity) have been reported to contain
LSCs [5–9]. The first LSC compartment that was described had
the CD34+CD38- immunophenotype [2,3]. Although immune
reactivity of the CD38 antibody used in earlier studies likely
caused the lack of engraftment of CD38+ cells [10], the CD34+
CD38- compartment still seemed to be the most robust
compartment in CD34-positive (CD34+) patients, since it was
found to be the predominant compartment containing leukemia-
initiating cells in less immunocompromised mouse models [3]. On
the other hand, in more severely immune-compromised mouse
models, CD34+CD38+ and CD34-negative compartments were
also found to contain leukemia initiating cells [5,7–9,11].
In bone marrow (BM) of AML patients, leukemic and normal
cells are present within one compartment. The CD34+CD38-
compartment in particular, was shown to contain both CD34+
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CD38- LSCs and normal hematopoietic stem cells (HSCs) [10,12].
Previous papers reported only on the role of the size of the total
CD34+CD38-stem cell compartment and only at diagnosis [13–
17]. However, for proper identification of LSCs, with the aim to
establish the prognostic impact of their frequencies at diagnosis
and to follow their fate during and after therapy, it is important to
identify distinguishing features between LSCs and HSCs. We
previously have found that in a substantial number of AML cases,
CD34+CD38- LSCs are characterized by the expression of C-type
lectin-like molecule-1 (CLL-1) and aberrant expression of several
lineage markers [18,19]. Since these markers are absent on HSCs
in regenerating BM after chemotherapy [18,19], for the current
study we chose to use these markers to distinguish between LSCs
and HSCs in both diagnosis and post-diagnosis samples. Other
LSC markers have also been described for AML diagnosis
(reviewed in ref [20]), but since little is known about their
behavior during and after therapy, their suitability for LSC
tracking remains to be established. However, despite the usefulness
of CLL-1 and lineage markers, in at least 25% of the AML
patients, aberrant marker expression on CD34+/CD38- cells is
absent or too weak, and therefore there is a need to identify other
discriminative parameters [6,19]. In the first part of this paper, we
will describe such additional parameters for CD34+CD38-
compartment. Now being able to discriminate neoplastic from
normal CD34+CD38- cells, in the second part we will focus on the
prognostic role of the CD34+CD38- stem cell compartment. This
will be compared with the other CD34/CD38 defined compart-
ments.
Moreover, another important aspect of cancer stem cells is their
putative therapy resistance [21], with a subsequent ability to cause
re-growth. The present study is the first to address the resistance to
therapy by showing the prognostic impact of AML stem cells post-
therapy in a large patient group. The results demonstrate that
defining residual LSCs post-therapy has important prognostic
impact. Moreover, we show that it adds important prognostic
impact to a well-established immunophenotypical MRD ap-
proach, known to identify and quantify the bulk of neoplastic cells.
Patients, Material and Methods
More detailed information can be found in the supporting text
(Text S1).
Patient treatment and sampling
Patients between 18 and 60 years of age with AML, except
those with FAB M3 and previously untreated RAEB and RAEB-t
patients (with IPSS $ 1.5), were included in this study. Detailed
information regarding treatment can be found at http://www.
hovon.nl. The HOVON/SAKK 42a and 92 studies were
reviewed and approved by an institutional review board (METc)
of the Erasmus MC Rotterdam for the total study (number 2000-
220 for Hovon 42a) and 2008/216 for Hovon 92). In addition, the
VU Amsterdam review board approved both studies with METc
number 2001/50 (LUV) and 2008/292 (LUV), respectively.
Patients provided their written informed consent to participate
in this study. In 250 CD34-positive patients, we used a specific
gating strategy to identify normal and neoplastic cells in the
CD34+CD38-, CD34+CD38+ and the CD34- compartment at
diagnosis. Patient details are in Table S1 (patient groups 1 and 2).
Additionally, in the last part of the results, an extra patient group
(n = 23) was included (details are in Table S1, patient group 3) to
study combination of LSC and minimal residual disease (MRD)
data after second cycle of therapy.
Flow cytometry
Methods. LSC characterisation at diagnosis and LSC mon-
itoring during follow up was performed on fresh patient samples.
Purified white blood cells were obtained from BM or PB using
lysing solution (Pharm lyse, Becton Dickinson, BD, San Jose, CA,
U.S.A.) to eradicate red blood cells. After washing with PBS
containing 0.1% human serum albumin (HSA), cells were re-
suspended in PBS containing 0.1% HSA, incubated with
monoclonal antibody combinations (mAbs) for 15 minutes at
room temperature and washed with PBS containing 0.1% HSA.
Details on antibodies (sources, clones, fluorochromes) are written
in the supporting text (Text S1). Samples were analysed using a 4-
color approach on a FACSCalibur from Becton Dickinson (BD,
San Jose, CA, USA) using CellQuest and Infinicyte software. Cell
sorting was performed using FACSAria (BD) with FACSDiva
analysis software. More details are in the supporting text (Text S1).
Marker selection for the CD34+CD38- LSC. In a previous
paper [19], we have shown that particular lineage markers, i.e.
CD2, CD7, CD11b, CD19, CD22, CD56, can be positive on
CD34+CD38- LSC, while always negative on CD34+CD38-
HSC. This is true for CLL-1 too [18]. All markers have been
shown to be negative on HSCs in normal bone marrow, but also
on normal stem cells present at diagnosis and at follow up [18,19].
In addition, the absence of CD13, CD33 and HLA-DR was
considered aberrant, since these markers are always expressed on
normal HSCs [19,22]. For each new AML case one or more of
these markers may be aberrantly expressed; in a next case this may
be completely different. Therefore, for each new AML case, the
choice for a marker was based on screening for presence (.10%
positivity) of all markers. Even more heterogeneity was seen, since
part of the CD34+CD38- population might be negative for these
markers, and all or not covered by another marker.
Marker selection for the more mature CD34+CD38+ and
CD34- populations. For CD34+CD38+ and CD34- leukemic
cells, identification had to be done using lineage markers: it is only
lineage markers that are absent (or present at very low frequencies)
on these more mature populations [23,24]. This property offers
the basis for detection of residual leukemic cells (all leukemic cells)
in MRD approaches. CLL-1, however, cannot be used as a
neoplastic marker on CD34+CD38+ and CD34- cells since it is
present on part of these populations in normal bone marrow [25].
For LSC identification/quantification at diagnosis and follow up,
only AML samples were used that, at diagnosis, showed.1%
CD34 expression relative to the total WBC count. This was done
because we have previously shown that the CD34+ population in
AML with ,1% CD34 is of normal origin [26]. CD34 negative
AML samples, together with normal bone marrow, were used as a
control for FSC/SSC values in HSC (see results section I.A). For
details on the gating strategy to define the CD34+CD38-
compartment, see Figure 1, part I. The details how to define
scatter characteristics of marker positive and marker negative
populations are outlined under Results. Stem cell numbers (LSC
and HSC) were defined as a percentage of total white blood cells
(WBC).
Engrafting studies
Animal experiments were performed after approval of the
animal ethical committee of the VU University, Amsterdam, The
Netherlands under DEC-number: KNO06-02. NOD/SCID IL-
2Rc -/- mice were obtained from the Jackson laboratory (Bar
Harbor, ME, USA). At the age of 8-10 weeks, the mice were
irradiated sub-lethally with a dose of 350 cGy, 24 hours prior to
transplantation of the human AML cells. Details of irradiation,
anesthesia, intravenous and intra-femoral injection are outlined in
Leukemic Stem Cell Frequency in AML
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the supporting text (Text S1) under ‘‘Patients’’. Human leukemic
and multi-lineage engraftment was determined based on positivity
for CD45-PercP, the presence/absence of CD19-positive B-cells,
CD13 and/or CD33-positive cells and, in three cases, by the
presence/absence of aberrant marker expression.
Engraftment was defined as a clear clustered population in
CD45 expression in a minimum of 200,000 acquired mice marrow
cells. The minimum percentage of human engraftment that was
detected was 0.1%, which shows up as a cluster of 200 cells on the
scatterplot. Human leukemic engraftment was determined based
on positivity for CD45-PercP, the absence of CD19-positive B cells
and the presence of CD13 and/or CD33 positive cells: when
CD13 was aberrantly absent on the AML that was injected, CD33
was used and when CD33 was absent, CD13 was used. Human
multi-lineage engraftment was identified when CD45 positive cells
consisted of both CD19 positive B-cells and myeloid cells with
both CD13 and CD33 present (identified as monocytes and/or
Figure 1. Gating strategy for the CD34+CD38- compartment and identification of pLSCs and HSCs in this compartment. I. Gating of
CD34+CD38- AML cells. Cells were labeled with antibody-fluorochrome combinations as described in Patients, Materials and Methods. Remaining
erythrocytes, debris and dead cells are largely excluded in an FSC/SSC plot (A). CD45dim/SSCdim blast cells (B) were gated to homogeneity in FSC/SSC
plot (C). CD34 positive cells are gated (D) and the CD38- stem cells are gated within this fraction (E). The CD38-negative fraction in D may contain two
stem cell populations differing in CD34 expression (details in text). F. Within the CD34+CD38- gate, CD38 is plotted against an aberrant marker (in this
case CD19) to indicate presence of putative LSCs (pLSCs) and HSCs. II. Identification of pLSCs and HSCs. This patient (nr 317) was diagnosed with
t(8;21). Primary gating was as in I. Sorted CD34+CD38-/CD19+ cells (A, in red) were t(8;21) positive; sorted CD34+CD38-/CD19- cells (A, in green) were
t(8;21) negative. These two populations were backgated in FSC/SSC (B,E), CD34/SSC (C,F) and CD45/SSC (D,G) plots. The CD19- cells are shown in the
upper panels and the CD19+ cells in the lower panels. Dotted vertical lines (B–D) show that normal CD19- cells are FSClow (B), CD34low (C) and slightly
lower in CD45 (D), compared to CD19+ cells (E–G). The dotted horizontal line shows that SSC of the normal stem cells (in green) was slightly lower
than that of neoplastic stem cells (in red). FISH data are from an example published previously [19]. Similar results were found in an additional series
of 7 patients (Tables 1 and 2). FSC and SSC of CD19+ pLSC were factor 1.71 and 1.77 higher than lymphocyte present in the same samples. FSC and
SSC of the CD19 negative cells were only 1.08 and 1.20 times lower than lymphocytes.
doi:10.1371/journal.pone.0107587.g001
Leukemic Stem Cell Frequency in AML
PLOS ONE | www.plosone.org 3 September 2014 | Volume 9 | Issue 9 | e107587
granulocytes in a FSC/SSC plot), and with absence of aberrant
markers.
FISH, FLT3-ITD and NPM1 analysis
For the FISH analysis, cytospins were prepared with FACS-
sorted cells. LSI AML1/ETO dual color for t(8;21) probe (Vysis,
Abbott molecular, Illinois, U.S.A.) was applied to the denatured
cells and incubated as previously described [17]. Genomic DNA
from sorted cell populations was analyzed for the presence of an
FLT3-ITD as described before [27]. Mutations in NPM1 exon 12
were analyzed by PCR using genomic DNA that had been isolated
from sorted cell fractions (see Text S1).
Survival analysis
Statistical analysis of the stem cell data at follow-up was carried
out using the SPSS 20.0 software program. The supplement
provides details regarding the definition of overall survival (OS),
event-free survival (EFS), relapse-free survival (RFS), Kaplan-
Meier analyses, and Cox regression analyses for both univariate
and multivariate analyses. P-values below 0.05 were considered
significant.
Results
In the absence of formal proof of leukemia initiating ability in
the stem cell compartments of most of the samples studied, the
different stem cell compartments are referred to as putative LSCs
(abbreviated as pLSC).
Since the aim of the study was to define the prognostic impact of
the neoplastic CD34+CD38- compartment, and to compare with
the neoplastic CD34+CD38+ and CD34 negative compartments,
first, properties will be described that allow to discriminate
between the neoplastic and the normal compartment within the
CD34+CD38- compartment (Section I.A–D) and the CD34+
CD38+ and the CD34- compartments (Section I.E). Proof of the
resulting concept was obtained using either molecular biological
and/or murine engraftment experiments.
In Section II. the findings were used to assess the prognostic
impact of the number of pLSCs at diagnosis and post-therapy for
the CD34+CD38- compartment (II.A,B) and the CD34+CD38+
and CD34- compartment (II.C,D). Finally, the prognostic impact
of the combination of follow up CD34+CD38- pLSC frequency,
with MRD data will be described (II.E).
I. Discrimination between leukemic and normal stem cell
compartments
A. CD34+CD38-: discrimination of pLSCs and HSCs can
be made based on aberrant marker expression and scatter
properties. We have previously shown that the expression of
aberrant markers on CD34+CD38- cells indicates the leukemic
nature of stem cells [18,19]. Figure 1.II illustrates the difference
between CD34+CD38- pLSCs and HSCs based on aberrant
marker expression and molecular aberrancies [in this example,
t(8;21)]. In addition to Figure 1, Table 1 shows 7 other patients
with aberrant marker positive cells, all with molecular aberrancies
indicating that these are in fact neoplastic cells. The figure also
shows that marker-positive pLSCs, compared to HSCs, are further
characterized by a tight clustered cell population with higher
forward scatter (FSC, reflecting cell size) and higher sideward
scatter (SSC, reflecting granularity). This phenomenon was found
in the other patients of Table 1 too (shown in Table 2). In
Table 2, FSC and SSC of lymphocytes were used as internal
controls to define the FSC/SSC position of pLSC and HSC.
pLSC and HSC may also differ in CD34 and CD45 expression (in
the case of Figure 1, CD34 expression of pLSC was higher than
HSC). Such differences were not consistent but helped to define
clusters of cells especially in cases with very low numbers of cells
and/or small differences in aberrant marker expression and/or
FSC/SSC.
Table 1. Molecular status of diagnosis total AML and sorted stem cell fractions from the same BM.
Patient
nr
Molecular status
of AML blasts1
Aberrant marker
expressed
onCD34+CD38- cells* CD34+CD38- aberrant marker negative CD34+CD38- aberrant marker positive
CD34+CD38-
aberrant marker-
% aberrant marker-
of CD34+CD38-$
CD34+CD38-
aberrant marker+
% aberrant marker+
of CD34+CD38-
317¥ t(8:21) pos CD19 t(8;21) neg 23 t(8:21) pos 77
808 50% FLT3-ITD# CD33- wt 67 45% ITD# 33
NPM1 mut CD33- wt 67 NPM1 mut 33
945 NPM1 mut CLL-1 wt 47 NPM1 mut 53
951 42% FLT3-ITD CLL-1 wt 46 60% ITD 54
966 43% FLT3-ITD CD7 wt 41 41% ITD 59
1263 60% FLT3-ITD CD33- wt 2.5 80% ITD 97.5
575 50% FLT3-ITD CD33- wt 58 50% ITD 42
NPM1 mut CD33- wt 58 NPM1 mut 42
670 NPM1 mut CLL-1 wt 74 NPM1 mut 26
1signal originating from the bulk of the leukemic blasts has been used for reference. Sorted lymphocytes from the same BM showed no molecular aberrancies.
*Aberrant markers with the highest coverage of the CD34+CD38- compartment were used for sorting HSC (aberrant marker negative) and pLSC (aberrant marker
positive).
¥Shown in Figure 1.
#For FLT3-ITD+ cases, the percentage of ITD of the total signal is indicated.
$Median frequency of HSCs (46.5% of CD34+CD38- compartment) was higher than the median in a larger group of cases (median 18%), since cases in this table had to
be selected on clear availability of both HSCs and pLSCs.
Abbreviations: wt, wild type: no FLT3-ITD or NPM1 peak present; mut: mutation of NPM1 (not quantitative), neg: negative, pos: positive, BM: bone marrow.
doi:10.1371/journal.pone.0107587.t001
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Table S2 shows the FSC/SSC position relative to lymphocytes
of CD34+CD38- HSCs present in normal BM, as well as CD34+
CD38- present in CD34 negative AML, which have previously
been shown to be normal [26]. FSC/SSC of HSCs present in
these controls are all lower than pLSC present in CD34+ AML
(Table S2). Moreover, HSC present in CD34+ AML also have low
FSC/SSC and altogether there is not even overlap in FSC/SSC
between pLSC in CD34+ AML and the HSCs present in these
three bone marrow sources. This allows accurate definition of the
nature of a population especially in those cases with only a single
population present.
B. CD34+CD38-: is there a role of FSC/SSC to define
pLSC and HSC in aberrant marker-negative part of
CD34+CD38- compartment?. Aberrant markers may cover
only part of neoplastic CD34+CD38- cells [19]. We therefore
investigated whether scatter differences may help to discriminate
pLSCs from HSCs in aberrant marker-negative cells. This was
indeed seen as illustrated for patient sample 456 in Figure 2.I. The
investigation of expression of only aberrant markers would have
led to an over-estimation of HSC numbers and an under-
estimation of pLSC numbers. Figure 2.II provides more examples.
In approximately 25% of AML cases, there is no clear aberrant
marker expression in the CD34+CD38- compartment, and in even
more cases, marker expression is weak and overlaps with the
marker negative cells [19]. In order to nevertheless discriminate
between pLSCs and HSCs, we investigated whether scatter might
replace marker expression in this respect. Figure 3 (A–D) shows
that, even without clear aberrant marker expression (CD19 covers
only a very low frequency CD34+CD38- population), differences
in scatter can be used. Since, in this particular AML case, aberrant
expression of CD7 was found (Figure 3 E–F), the validity of the
scatter approach could be demonstrated (compare Figure 3 E–F
with D). This shows that the scatter approach allows to
discriminate pLSC and HSC in the absence of aberrant markers.
C. CD34+CD38-: discrimination between HSCs and
pLSCs in a large patient group using marker and scatter
differences. In cases with differences seen in FSC and SSC
between pLSC and HSC, pLSC always had higher FSC/SSC
than HSC. However, at this point it should be emphasized that
differences in scatter were found in part of the patients. In 250
diagnosis AML cases studied, the combination of marker
expression and FSC/SSC differences allowed accurate identifica-
tion of both pLSCs and HSCs in 117/250 cases (47%), (outlined in
detail in Table S3 and summarized in Table S4. For reasons
mentioned earlier, differences in expression of CD34 and CD45
were only used for fine-tuning. As might be expected, the pLSC
compartment made up the majority of the total CD34+CD38-
compartment (median of 82%, ranging from 0%–100%). Apart
from these 117 cases, there was an extra group of 102 patients
(41%) with only marker expression available, while 31 patients
(12%) had no marker and scatter properties usable for pLSC
detection (summarized in Table S4).
D. CD34+CD38-: multilineage and leukemic engraftment
of CD34+CD38- HSCs and CD34+CD38- pLSCs in NOD/
SCID IL-2R c-/- mice. To provide further proof of principle for
the strategy based on marker expression, secondary gating and
molecular profiles, murine engraftment experiments were per-
formed. HSCs were sorted by marker negativity, and clustering as
FSC/SSClow, and/or distinct CD34/CD45 clustering, injected
intrafemorally and evaluated for engraftment. In 5/6 cases,
multilineage engraftment was found with no signs of leukemia
(Figure 4, Table S5). In accordance with our in vitro gating
strategy, AML engraftment with low cell numbers was observed in
2/6 cases for CD34+CD38- marker-positive samples and in 1/6
cases for the CD34+CD38- marker-negative cells, the latter being
identified as neoplastic based on high FSC and aberrant CD34
expression (see legends of Table S5).
E. CD34+CD38+ and CD34-: discrimination between
normal and leukemic CD34+CD38+ and CD34- cells and
their leukemic engraftment in NOD/SCID IL-2R c-/-
mice. Although emphasis in this paper is on the CD34+
CD38- compartment, results described later for prognosis of
CD34+CD38- pLSC will be compared with the other CD34/
CD38 defined compartments. To enable such, neoplastic CD34+
CD38+ and CD34- cells were identified by aberrant expression of
markers used to define so-called Leukemia Associated (Immuno)
Phenotypes established at diagnosis and used by others and us
[23,24] for detection of minimal residual disease. Cells were sorted
as described in Text S1. In agreement with recent reports, these
cell compartments also had leukemia initiating potency since AML
engraftment was found in 4/6 cases for the CD34+CD38+
compartment and in 2/6 cases using CD34- compartments
(referred to in the legends of Table S5). In all but one case, this
was accomplished with high cell numbers (100,000-1,000,000).
Table 2. FSC/SSC position relative to lymphocytes.
Patient nr Aberrant marker negative CD34+CD38- Aberrant marker positive CD34+CD38-
FSC/SSC position* FSC/SSC position*
317¥ 1.08/1.20 1.71/1.77
808 1.27/1.17 1.57/1.80
945 1.38/1.52 1.97/3.25
951 0.93/0.77 1.46/1.39
966 1.15/1.0 1.53/1.99
1263 1.04/1.22 1.39/2.08
575 1.06/1.02 1.34/1.77
670 1.21/1.07 1.52/1.73
¥Shown in Figure 1.
* FSC/SSC values are based on the position of cells in FSC/SSC relative to the
FSC/SSC position of normal lymphocytes in the same BM sample.
The molecular status of the sorted cell fractions is summarized in Table 1.
doi:10.1371/journal.pone.0107587.t002
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II. Prognostic role of putative stem cell compartments
To assess the clinical impact of our findings, we assessed the
prognostic value of the size the three individual LSC compart-
ments both at diagnosis and, where applicable, especially at
clinical follow-up.
A. CD34+CD38- at diagnosis. To assess prognostic impact,
different cut-off values were established to define patients with
high pLSC count (above the cut-off level: referred to as pLSC+)
and patients with low pLSC count (below the cut-off level: pLSC-).
Patients who later turned out not to have achieved complete
remission (non-CR patients) had median 6-fold higher pLSC
count than patients who had achieved CR (see legends of
Figure 5). Moreover, the CR patient group could be divided into
two groups with significantly different prognoses at multiple cut-off
points ranging from 0.002% to 1% (Figure 5A and Table S6A).
Figure 5B shows that further splitting up the CR group resulted in
the definition of three groups with large differences in relapse-free
survival (RFS). The latter result was also found upon inclusion of
non-CR patients (not shown) and replacement of RFS by EFS
(Figure 5C). Multivariate analysis showed pLSC frequency to be
an independent prognostic factor (Figure 5, legends).
Figure 2. Marker-negative cells may contain leukemic cells defined by aberrant scatter. I. Gating/sorting strategy and molecular
analysis for patient 456. CD34+ CD38- cells (patient 456, figure 2) were gated as in figure 1. CD34+CD38- cells were either CD7-negative (green in
A and C, 25% of CD34+CD38-) or CD7 positive (red in A and D, 75% of CD34+CD38-). CD7+ cells were FSC/SSChigh (D) and of neoplastic origin (H).
CD7-negative cells were further subdivided into FSC/SSClow (left of the broken line in C), and FSC/SSChigh (right of the broken line in C). The CD7-
negative, but FSC/SSChigh, cells were neoplastic (G), while the CD7-negative FSC/SSClow cells were essentially normal (F). CD34+ cells was the positive
control (E). II. Molecular analysis of stem cell subpopulations in four patients. Sorting and analysis was done as in figure 2.I A for 3 additional
patients. # FLT3-ITD (% of total signal: FLT3-ITD + wt) determined in cell populations sorted from CD34+ AML patients. * shown in figure 2.I A. 1 FSC/
SSClow and FSC/SSChigh defined as outlined in Table 2.
doi:10.1371/journal.pone.0107587.g002
Leukemic Stem Cell Frequency in AML
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B. CD34+CD38- during follow-up in CR. The gating
approach shown in Figure 1 was used to follow the fate of pLSCs
over time using sequential sampling (examples in Figure S1). Cox
regression analysis showed a strong significant inverse correlation
between the pLSC percentage after all therapy cycles and RFS
and OS (for details, see legends to Table S7). Kaplan-Meier
analyses showed markedly improved RFS and OS in pLSC-
patients compared with pLSC+ patients (example in Figure 6, A–
C), which applies for a large range of cut-off values (Table S7).
Multivariate analyses with cut-off values showed that pLSC
frequency after the first and second treatment cycles was an
independent prognostic factor for RFS and OS (example with
0.0003% and 0.0001% shown in Table S8).
C. CD34+CD38+ and CD34- at diagnosis and at follow
up. The CD34+CD38+ and CD34- compartments have been
shown to contain leukemia initiating cells [5,11] (also in this
paper). In order to assess whether these were clinically important,
when present together with the leukemia initiating CD34+CD38-
compartment, we assessed their prognostic impact.
At diagnosis, neoplastic CD34+CD38+ and CD34- blast cells
were identified as described under I.B. For CD34+CD38+, there
was no single cut-off value (tested in the range 2%–60%) that
resulted in discrimination of two patient groups with different RFS
(Figure 5D; Table S6B), even when non-CR patients were
included in the latter (data not shown). Although only borderline
significant, in contrast to CD34+CD38-, the neoplastic CD34+
CD38+ compartment was even smaller in non-CR patients than in
CR patients (10.8% of WBC versus 23.7% of WBC; p= 0.06).
Similar results were obtained for the CD34- compartment with
cut-off points ranging from 0.1%–30% (Figure 5E; Table S6C),
with the neoplastic compartment size, similar to CD34+CD38+,
being even smaller (albeit non-significantly) in non-CR patients
than in CR patients (0.87% of WBC versus 2.41% of WBC,
p= 0.48).
At follow up, the neoplastic component of the CD34+CD38+
and CD34- compartment represented a considerable portion of
the total neoplastic blast compartment. This reflects the total
leukemic burden, or MRD, which, in turn, has previously been
shown by many authors, including ourselves, to have prognostic
impact (see also next paragraph) [23,24].
D. Post-diagnosis prognostic impact of CD34+CD38- LSC
combined with MRD. The burden of leukemic stem cells after
chemotherapy does not always reflect the total leukemic burden
(known as MRD). It can thus be argued that the combination of
pLSC frequency and MRD frequency may improve prognostic
information at follow up. Because this combination would divide
Figure 3. Marker negative pLSCs co-exist with marker positive pLSCs and are identified by scatter and CD34/CD45 expression
patterns. CD34+ CD38- cells (patient 372) were identified as described in figure 1.I and gated for sub-compartments as described for figure 2.I. In
the stem cell compartment of this AML case, only 11% could be identified as CD19+ (A). When back-gated in FSC/SSC (similar as performed in
Figures 1 and 2), two different populations were identified based on the position in FSC/SSC: the small CD19+ fraction (events in red in A–D) is
characterized by FSC/SSChigh (B), low CD34 expression (C) and high CD45 expression (D). CD19 negative cells (events in green in A–D), apart from a
small FSC/SSClow/CD34high/CD45low population of putative HSCs (A–D), contained a large population of cells that, similar to the CD19+ population in
A–D, were FSC/SSChigh (B), CD34low (C), and CD45high (D). Apart from CD19, CD7 was an aberrant marker: 61% of the cells was CD7+ (E). Upon
backgating, CD7+ cells (events in red in E–H), similar to CD19+ cells, were all FSC/SSChigh (F) CD34low (G) and CD45high (H). In contrast to CD19, CD7
negative cells (events in green in E–H) now completely consisted of a small FSC/SSClow (F), CD34high(G), CD45low (H) fraction. CD7 thus covered the
whole neoplastic CD34+CD38- population and shows perfect discrimination between HSC and pLSC. CD19 expression in the absence of both CD7
expression and other scatter and CD34/CD45 expression parameters would have under-estimated the pLSC in the CD34+CD38- compartment by a
factor 5.5 (61%/11%), while the HSCs would have been over-estimated by a factor 2.3 (89%/39%). In this case CD7 was a good marker to compare
with the poor CD19 marker; it can be seen, however, that in the absence of CD7 expression, but with the scatter and CD34/CD45 aberrancies present,
these would have enabled a complete discrimination between putative HSC and LSC compartments. This patient was identified as NPM1-positieve
and FLT3-ITD positive. Other molecular aberrancies were not detected.
doi:10.1371/journal.pone.0107587.g003
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the total patient group in four relatively small sub-groups defined
by both a pLSC cut-off (Figure 6, Table 3) and a fixed MRD cut-
off of 0.1 [24]), we increased the size of the present patient
remission group by including 23 similarly treated young adults in
remission (,65 years) (details in Table S1 ‘‘Patients 3’’). In the
total group (n= 91) pLSC frequency again had strong prognostic
impact over a range of cut-off points (from 0 in 106 WBC up to 10
in 106 WBC. As an example, the cut-off point of 0.0001% is shown
in Figure 7A. For MRD, the cut-off point of 0.1% had the
expected prognostic impact (Figure 7B) [24]. When combining
MRD and pLSC in Figure 7C, four groups were identified. The
main conclusions from this figure are: 1) within the total MRD-
group (n= 64), pLSC+ patients (n = 31) have significantly poorer
prognosis than pLSC- patients (n = 33; p= 0.01); 2) within the
pLSC+ group, MRD- patients, although having a relatively poor
prognosis, may do better than MRD+ patients (p = 0.04); the
pLSC-/MRD- group had relatively good prognosis, while the
pLSC+/MRD+ group had very poor prognosis.
Figure 4. Multilineage engraftment of CD34/CD38 and scatter-defined putative HSCs. Unsorted mononuclear cells (MNCs) were injected
intravenously and resulted in leukemic engraftment: cells were CD45+ (A) and of myeloid origin (B). In this case, the myeloid cells were positive for
the diagnosis of leukemia-associated phenotype (LAP): partly CD33+CD13- (C) and CD11b+ (D). Sorted putative HSCs were injected intrafemorally
(details, see Table S5). Engrafted CD45+ cells (E), contained both B-cells and myeloid cells (F), and lacked LAP (G,H). Multilineage engraftment of the
sorted subpopulations was seen for patient 598 (I), 661 (J), 423 (K), and 928 (L). B-cells and myeloid cells (percentage of CD45+ cells) are in the upper
left and lower right corners of the plots, respectively. The AML cells of patients 598 (I) and 661 (J) had an aberrant phenotype at diagnosis that was
present in the neoplastic engrafted cells, but absent in the normal cells (not shown).
doi:10.1371/journal.pone.0107587.g004
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Figure 5. Prognostic value of frequencies of pLSC compartments at diagnosis. This figure shows the Kaplan-Meier analyses at diagnosis for
the three compartments putatively containing pLSCs: CD34+CD38- (A,B,C), CD34+CD38+ (D) and CD34- (E). Of the 117 patients shown in Table S3, for
Figures 5 and 6, 88 patients were chosen who had at least one follow-up time point. Of these, 70 entered Complete Remission, of whom 53 after the
first course, 13 after the second course and 4 at later stages. Eighteen never reached CR. The size (median values) of the CD34+CD38- compartment at
diagnosis was significantly (six-fold) higher in patients who did not enter CR (n = 18) compared with patients who did (n = 70): 0.225% of WBC versus
0.036% of WBC (p= 0.041). For CD34+CD38+ and CD34-, there were no significant differences (see text). Cut-off levels were defined to divide the total
population into high stem cell frequencies (above cut-off) and low stem cell frequencies (below cut-off). A particular cut-off value was chosen (A, D, E)
to ensure approximately equally numbers of patients in the resulting high and low stem cell frequency compartments. Results for other cut-offs for
the three pLSC compartments are in Table S6. A–C: CD34+CD38-; D: CD34+CD38+; E: CD34-. A. RFS in remission patients (n = 70) with diagnosis
CD34+CD38- cut-off of 0.03%; B. RFS in the same patient group (n = 70), but now with 2 cut-offs (0.005% and 0.1%); C. Event-free survival for all CR
and non-CR patients (n = 88); D. RFS in remission patients (n = 70) with CD34+CD38+ cut-off of 25%; E. RFS in remission patients (n = 70) with CD34-
cut-off of 3%. All relevant prognostic variables with statistical significance were investigated in a multivariate model. In this multivariate analysis it
was found that risk group (according to the HOVON 102 trial) was an independent prognostic factor for OS at diagnosis (p = 0.001). For RFS, both risk
group and CD34+CD38- leukemic stem cell load (using a 0.03% cut-off point) were independent prognostic factors at diagnosis (p = 0.017 and
p= 0.011, respectively).
doi:10.1371/journal.pone.0107587.g005
Figure 6. Prognostic value of frequencies of CD34+CD38- pLSC compartment at follow-up. This figure shows the Kaplan-Meier analyses
for RFS for the CD34+CD38- pLSC compartment at follow up for three consecutive therapy cycles. The optimal cut-off levels were chosen to define
pLSC + and pLSC- after 1st induction cycle (0.0003%,which is 3 pLSCs in 1,000,000 WBC) and after 2nd induction cycle and consolidation therapy
0.0001% (1 pLSC in 1,000,000 WBC). Results for other cut-offs are in Table S7. After the first induction cycle (B, 71 patients), second induction cycle (C,
77 patients), and after consolidation therapy (D, 48 patients), patients with high pLSC frequency (pLSC+) showed significantly more adverse
performance compared with patients with low pLSC frequency (LSC-).
doi:10.1371/journal.pone.0107587.g006
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When including the distribution of cytogenetically/molecularly
good, intermediate, poor and very poor patients, these were all
represented in the four LSC/MRD defined subgroups (Table 3).
This shows that, the pLSC/MRD prognostic impact is across
cytogenetic risk groups, although in the LSC+/MRD+ group poor
and very poor cytogenetic/molecular risk groups are prevalent.
When including the post-diagnosis prognostic parameter ‘‘cycle
after which CR is reached’’ in Figure 7, it turned out that there
was no significant difference between the first three pLSC/MRD
defined patient groups in number of cycles needed to reach CR: in
the first group (pLSC-/MRD-) 29 after first cycle versus 4 after
second cycle; in the third group (pLSC+/MRD-) this was 25
versus 6. The second group (pLSC-/MRD+) was too small (all
patients in CR after one cycle). However, in the fourth group
(pLSC+/MRD+) for 9 patients two cycles were needed, with one
for the other 9 patients.
These data show that combining cytogenetic/molecular defined
risk groups together and clinical parameters like cycles to CR,
together with pLSC/MRD defined risk assessment may offer a
very important new algorithm in risk assessment.
Discussion
One of the major challenges in the design of new therapies to
eradicate leukemia stem cells is to achieve high therapeutic
specificity. To this end, it is important to distinguish LSCs from
the concomitantly present HSCs, and to assess whether this
distinction is of prognostic value, since it would underline the
clinical importance of LSCs. Consequently, it was necessary to
identify parameters that allowed discrimination between these
pLSCs and HSCs, preferably in all AML cases. Recent studies
have shown that pLSCs may reside not only in CD34+CD38-, but
also in CD34+CD38+ and CD34- compartments [5,11]. In the
present paper, we first present methods to discriminate between
the neoplastic and normal portions of these compartments, and we
subsequently assessed the prognostic value of these putative stem
cell compartments.
With regard to the prognostic impact, using a uniquely-designed
multi-parameter flow cytometry protocol, we show for the first
time that the CD34+CD38- pLSC load after different cycles of
therapy was highly predictive of patient survival, independent of
other prognostic parameters. In addition, following our own
preliminary studies [13], we identified three patient groups at
diagnosis defined by CD34+CD38- pLSC with very large
differences in prognosis, again independent of other prognostic
parameters. By comparison with literature [13–15], it can be
appreciated that the prognostic impact using our new approach, in
which the pLSC compartment within the total CD34+CD38-
compartment was specifically used, is much higher than using the
total CD34+CD38- compartment as done in the previous studies.
This is likely due to the ‘‘contamination’’ of the leukemic CD34+
CD38- compartment with HSCs in the earlier studies (ranges of
0%–100% of pLSC, as seen in our study, also means that HSC
range from 0%–100%), as seen in Table S3. In contrast, the
CD34+CD38+ and CD34- compartments at diagnosis completely
lacked prognostic impact, which strongly suggests that CD34+
CD38+ and CD34- pLSCs are of minor clinical importance, at
least in AML cases where these compartments are accompanied
by CD34+CD38- pLSCs (as by definition is the case in our current
CD34 positive patient group). However, at follow-up, leukemic
Table 3. Role of cytogenetically/molecularly defined risk groups in pLSC/MRD defined sub-groups.
Group N (nr per pLSC/MRD sub-group) % per pLSC/MRD sub-group 40 months survival* (%)
sub-group (cytogen/mol)
pLSC-/MRD- (total) 33 100 74
good 8 24 69
intermediate 11 33 80
poor 10 30 80
very poor 4 12 50
pLSC-/MRD+ (total) 9 100 56
good 5 56 60
intermediate 3 33 67
poor 0 0 -
very poor 1 11 0
pLSC+/MRD- (total) 31 100 45
good 8 26 47
intermediate 7 23 57
poor 12 39 47
very poor 4 13 0
pLSC+/MRD+ (total) 18 100 16
good 4 22 25
Intermediate 2 11 0
Poor 7 39 15
Very poor 5 28 0
* 40 months was chosen as most survival curves had reached a plateau.
MRD cut-off: 0.1% of WBC, pLSC cut-off: 0.0001% of WBC.
doi:10.1371/journal.pone.0107587.t003
Leukemic Stem Cell Frequency in AML
PLOS ONE | www.plosone.org 10 September 2014 | Volume 9 | Issue 9 | e107587
CD34+CD38+ and CD34- compartments represent considerable
portions of the total leukemic burden and thus reflect MRD cell
frequency rather than pLSC frequency. Here, CD34+CD38+ and
CD34- cells probably originate from (limited) differentiation of the
CD34+CD38- pLSCs, a process that has been shown to occur in
vivo by Goardon and colleagues [28].
The results are compatible with the following model: what the
paper shows is that in CD34 positive AML cases, it is the
percentage of the CD34+CD38- population at diagnosis that
strongly correlates with clinical outcome and not the percentage of
CD34+CD38+ or CD34- cells. This does not mean that CD34+
CD38+ and CD34- cells do not contain leukemia initiating ability;
it simply strongly suggests that, in the presence of CD34+CD38-
cells, these CD34+CD38+ and CD34- leukemia initiating cells are
either less therapy resistant and/or less malignant compared to
CD34+CD38- cells. Likely, leukemia initiating ability in mouse
models of CD34/CD38 defined sub-populations do not reflect
clinical importance (see also next paragraph), since this ability is
Figure 7. Prognostic value of combined p-LSC andMRD. (A) Kaplan-Meier analyses after cycle II for RFS for the pLSC data as shown in Figure 6,
with an additional 23 patients (Table S1). The pLSC cut-off used is 0.0001%. (B) Kaplan Meier analysis of MRD data (cut-off 0.1%) obtained for the same
patient group as in A (n = 91). (C) Combined pLSC and MRD (n= 91) data resulted in 4 patient groups: pLSC-/MRD-, pLSC-/MRD+, pLSC+/MRD- and
pLSC+/MRD+.
doi:10.1371/journal.pone.0107587.g007
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always assessed using purified populations, whereby the ‘‘compe-
tition’’ between these populations in outgrow and/or the relative
therapy resistance cannot be taken into account. This model also
implies that in CD34 negative AML (with only neoplastic CD34-
populations present), it is the CD34- pLSC that takes over the
leukemia initiating ability. Also in CD34 positive AML in the
absence of CD34+CD38- cells, but with neoplastic CD34+CD38+
and CD34- populations present, the latter two populations may
take over the leukemia initiating ability. As a logical consequence
of the model these putatively less aggressive and/or less therapy
resistant populations should define a better clinical outcome,
which is indeed the case: in a separate cohort of 438 patients,
survival of CD34 negative patients was significantly better than
survival of CD34 positive patients (unpublished results).
The lack of correlation between prognosis and the size of the
different CD34+CD38+ and CD34- compartments, while all
compartments in purified form do engraft in a mouse model, may
be explained as follows: the overall immune status of a patient
group like that in our study, may best be represented by a less
immune-restricted mouse model, where CD34+CD38- pLSCs are
the predominant engrafting cells [29,30]. In line with that, in our
earlier engrafting experiments using CD34+ cells (i.e., containing
CD34+CD38-, CD34+CD38+ and CD34- cells) in the less
immune-restricted NOD/SCID mice, it was only the size of the
CD34+CD38- compartment at diagnosis that correlated with
levels of engraftment [13]. More immune-restricted mouse models
are useful to study LSC engraftment of probably less aggressive
pLSC sub-populations [5,28]. In this respect, an important initial
observation was made by Costello and co-workers, who found
that, in vitro, CD34+CD38- cells were more therapy-resistant and
less immunogenic than other compartments [21]. Moreover,
further compelling evidence that the CD34+CD38- compartment
is most important in the clinical setting comes from our clinical
observations: in most cases which had low frequency mutations at
diagnosis, which became predominant at relapse, these mutations
were present and/or enriched in the neoplastic CD34+CD38-
diagnosis compartment [31].
Survival and outgrowth of leukemia cells after therapy may
depend on many factors and include the LSC load and likely
specific LIC properties, but also the frequency of AML blast cells
referred to as MRD. Many authors, including us, have shown that
MRD is a strong independent prognostic factor [24,32,33]. In this
paper we have shown that both CD34+CD38- pLSC frequency
and MRD cell frequency are complementary, thereby defining a
new post-diagnosis combination factor that offers strong prognos-
tic information, even across cytogenetics/molecular defined risk
groups. This will prospectively be validated in a new patient cohort
of the HOVON/SAKK cooperative study group for which patient
enrollment has already started.
With regard to our approach to distinguish between pLSCs and
HSCs within the CD34+CD38- compartment, we have shown
that aberrant expression of antigens (including CLL-1) and lineage
markers, as well as additional aberrancies (including differences in
CD34 and CD45 expression and differences in light scatter) allow
unequivocal discrimination between pLSCs and HSCs. Moreover,
this approach even allowed CD34+CD38- pLSC detection in
patients lacking aberrant antigen expression. By applying the
additional parameters, underestimation of pLSC numbers or
overestimation of HSC numbers (often seen when using marker
expression alone) is avoided. The present study thereby confirms
the findings of others [29] that different CD34+CD38- pLSC
markers expressed in individual AML cases may miss substantial
portions of LSCs present (Figure 3). Although secondary param-
eters are thus very useful, it requires experience.
The number of accurately-identified pLSCs would increase with
the use of additional AML markers. Such markers may include:
CD123, CD96, CD44, CD47, CD25, CD32, CD33, TIM-3
[12,18,29,34–38]. In the present study, both lineage markers and
CLL-1 were used to identify CD34+CD38- pLSCs and HSCs
during follow-up, since these markers remained highly specific for
these LSCs during and after therapy [18,19]. To date, other
markers have not yet been tested and considerable efforts will be
necessary to demonstrate their applicability both for pLSC
quantification at diagnosis and especially at follow up, and as
putative targets in antibody therapies. In particular, undesirable
post-chemotherapy up-regulation on HSCs may occur for some of
these markers [18,19]. Thus, our study implies that, for adequate
pLSC (and HSC) tracking, a spectrum of markers and probably
additional parameters should be screened for each individual
AML case. Therefore, broad application of a single target antigen
for diagnostic purposes, as well as for future LSC-directed
antibody therapies, still seems unlikely.
Although FSC/SSC characteristics are often effective in
discriminating between CD34+CD38- pLSCs and HSCs, the
underlying cause of this difference is not yet known. An attractive
option is that, similar to normal stem cells, CD34+CD38- AML
sub-populations may exist with slightly different levels of
differentiation [28]. In fact, we now have more formal proof for
that: AML cases with high FSC and SSC of the CD34+CD38-
cells all have expression of the differentiation marker CD45RA. It
is known that this marker identifies GMP CD34+CD38+
progenitors in contrast to MEP and CMP CD34+CD38+
progenitors. We have found that CD45RA is completely absent
on the real CD34+CD38- HSCs, but marked corresponding
CD34+CD38- pLSC populations in roughly half of the AML
cases. In the other half, the pLSC had FSC and SSC close to those
of corresponding HSCs; these pLSCs were CD45RA negative.
The CD45RA positive cases may indeed reflect more progenitor-
like pLSCs compared to the CD45RA negative pLSCs that
resemble HSCs [28].
In AML cases with no malignant CD34+CD38- compartments,
the pLSCs will be located in the CD34+CD38+ and/or CD34-
compartments. It is likely, however, that within these relatively
large compartments, further compartmentalization will be neces-
sary to identify the true LSC sub-compartment which likely occurs
at low frequencies. One candidate fraction is the side population
(SP), which does occur in low numbers (usually ,1% of the WBC
population) and contains both normal and AML cells at diagnosis
[8,9]. Moreover, the SP has also been found to contain different
CD34/CD38-defined sub-fractions [6], which may represent
CD34/CD38/SP pLSCs. In the future, it would be interesting
to examine the relationships between the functional phenotypes
(based on SP or aldehyde dehydrogenase activity) [6–9,39,40] and
the CD34/CD38 immunophenotype.
In conclusion, the present study offers tools for detecting
concomitantly present pLSCs and HSCs, both at diagnosis and at
disease follow-up, and provides the first proof that CD34+CD38-
pLSCs are not only clinically important at diagnosis, but also at
follow-up. No evidence was found to suggest that the CD34+
CD38+ and CD34- leukemic fractions contain clinically important
LSCs, at least not in CD34 positive AML with leukemic CD34+
CD38- present. The combination with well-established MRD
assessment likely opens a new field in prognostication in patients
with AML. Ultimately, our findings may contribute to the
development of new diagnostic tools and to novel, more selective
therapies, including antibody-based therapies that would be highly
effective against AML stem cells, while leaving the normal HSCs
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intact. Finally, these results may stimulate further research into the
role of cancer stem cells in other cancers, such as solid tumors.
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showed CLL-1 expression in the CD34+CD38- compartment (A),
while normal BM misses CLL-1+ CD34+CD38- cells [1]. In CR,
CLL-1+ CD34+CD38- cells (B) were sorted and assessed for
t(8;21): mainly neoplastic cells were present (E). Normal CD34+
CD38-CLL-1 negative cells were almost completely absent here.
Shown in F-H are examples of sequential monitoring in three
cases with increasing periods of complete remission until relapse
(F, pt 253; G, pt 372) and in continuous remission (H, pt 572).
Note the increase of pLSC frequency preceding relapse (F, G).
(PPTX)
Table S1 Patient characteristics. *’’Patients 1’’ are all
CD34+ patients. ‘‘Patients 2’’ are all patients were accurate
discrimination between HSC and pLSC was enabled using our
extensive gating strategy. ‘‘Patients 3’’ are CR patients with MRD
and pLSC data to enlarge the total patient group as shown in
Figure 7.
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102/179 patients (41% of all 250 CD34+ patients, row 3), pLSC
frequencies may be under-estimated since additional gating
strategy (with FSC/SSC etc, referred to in columns 3–7) was not
possible, probably leaving part of marker negative pLSCs
unidentified. In 77 of these 179 patients, an additional gating
step could be performed (FSC/SSC etc, see row 4), allowing a
more accurate assessment of both pLSC and HSC frequencies. #:
,20% aberrant marker expression (71/250 cases) is shown in rows
5 and 6. In 31 cases (12%) only inadequate LSC assessment was
possible (row 5). However, in 40 of these 71 cases HSCs could still
be distinguished from pLSCs with the use of secondary parameters
(row 6). Highly adequate LSC assessment, using both aberrant
marker expression and secondary parameters was thus possible in
77+40 cases (47%). Columns show parameters/plots used to
distinguish HSCs from pLSCs.
(DOCX)
Table S5 Multi-lineage engraftment of marker negative
FSC/SSClow (CD34high) CD34+CD38- cells present in
AML. * in the missing mouse, engraftment could not be assessed
since this mouse died before examination was possible. # In the
missing mouse, no human engraftment was detected. In terms of
leukemic engraftment our results also confirmed the observation of
Bonnet’s group that purified CD34+CD38+ and CD34- were able
to engraft be it in our case after injection of high cell numbers.
CD34+CD38-/CLL-1+ in pts 1 and 2 (40,000 and 130,000 cells,
respectively) CD34+CD38-/CLL-1-/FSC high CD34low in pt 1
(6,000 cells) CD34+CD38+ in pts 2, 4, 5, 6 (high cell numbers,
100,000-106 injected in pts 2, 4, 6 and 1,000 in pt 5) CD34- in pts
2 and 5 (high cell numbers injected:100,000-106).
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Table S6 Cut-off values in the CD34+CD38-,
CD34+CD38+ and CD34- cell compartment at diagnosis
to identify patient groups with different survival. *p-
values refer to significance of differences in RFS between patients
above and patients below the indicated cut-offs.
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Table S7 Relative risk of relapse determined for pLSC-
and pLSC+ patients at follow up defined by different cut-
off points. Not shown in the Table: for RFS and OS, without use
of cut-offs, Cox regression analysis showed a strong significant
inverse correlation between pLSC percentage and RFS after 1st
cycle (n = 71, RR=2.4, 95%CI:1.3–4.6, p= 0.008), 2nd cycle
(n = 77, RR=2.5, 95%CI:1.7–3.7, p,0.001) and consolidation
cycle (n = 48, RR=3.0, 95%CI:1.4–6.2, p= 0.004). For OS, these
figures were RR=1.8 (p = 0.04), RR=2.7 (p,0.001) and
RR=2.0 (p= 0.07). Hereafter different cut offs were applied for
risk on relapse. RR, relative risk of relapse using these different cut
offs. Cut-offs of 0.0003% (3 in a million, 1st cycle) and 0.0001%
(2nd and consolidation cycle) were used for relapse-free survival
(RFS) in Kaplan-Meier analyses shown in Figure 6. With these
cut-offs median overall survival (OS, not shown in Figure 6) was
not reached (.42 months) for pLSC+ patients after 1st cycle, but
more patients survived in the pLSC- group (p = 0.002). After 2nd
cycle median OS in pLSC- group was.45 months versus 35
months in pLSC+ group (p,0.001). After consolidation cycle
these figures were both.37 months (p = 0.05).
(DOCX)
Table S8 Multivariate analysis# for impact of pLSC
frequency on RFS. # in univariate analyses performed on 162
CD34+ patients, cytogenetic/molecular risk (p = 0.001, n= 162),
number of chemotherapy cycles needed to achieve CR (p,0.001,
n = 162), and WBC count at diagnosis (p = 0.002, n= 162) were
significant. Other factors showed a trend: NPM1 mutation
(p = 0.093, n= 140) and EVI-1 (p = 0.18, n= 140). n.r. not relevant
since all evaluated patients achieved CR after first cycle RR,
relative risk of relapse. * only the most optimal cut-offs (0.0003%
after 1st cycle and 0.0001% after 2nd and consolidation cycle) are
shown.
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Text S1 Supporting text.
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